Four biotechnology firms are set to unveil clinical data for a new slate of cancer therapies at the American Society of Clinical Oncology (ASCO) annual meeting, a key event for investors where trial results can create or destroy billions in market value.
“ASCO provides an important forum to share advancements across our emerging and established CAR-T cell therapy programs,” Ying Huang, Chief Executive Officer of Legend Biotech, said in a company statement. “The rapid oral presentation for LB2102 underscores continued progress in extending CAR-T approaches into solid tumors.”
The conference, running from May 29 to June 2 in Chicago, will feature crucial updates from Legend Biotech (NASDAQ: LEGN), Asher Bio (NASDAQ: ASHR), Syndax Pharmaceuticals (NASDAQ: SNDX), and SKB BIO (06990.HK). Presentations include early results for CAR-T therapies in solid tumors, targeted immunotherapies for treatment-resistant melanoma, and new uses for an already-approved leukemia drug.
For investors, the data presented at ASCO is a critical catalyst. Positive results in key indications can validate a company's technology platform and significantly de-risk its pipeline, often leading to sharp stock price increases and partnership opportunities. Conversely, disappointing data can erase value and force strategic re-evaluations.
Legend's Solid Tumor Ambition
Legend Biotech will have a rapid oral presentation for LB2102, a CAR-T therapy targeting DLL3 in patients with relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). Chimeric antigen receptor T-cell (CAR-T) therapy, which reprograms a patient's own immune cells to fight cancer, has been highly successful in blood cancers, but progress in solid tumors has been limited. Early evidence of clinical activity for LB2102 could be a significant step forward. The program is part of a licensing agreement with Novartis, which is responsible for development beyond the current Phase 1 trial.
Asher Bio Targets Refractory Melanoma
Asher Bio will present updated Phase 1A/B data for AB248, its CD8+ selective IL-2 immunotherapy. In a heavily pretreated group of patients with cutaneous melanoma, the therapy showed an 18% objective response rate (ORR) as a monotherapy. In combination with pembrolizumab for IO doublet-refractory melanoma, the ORR was 30% in patients treated at the 0.3 mg/kg dose. The company noted that AB248 achieved this with a manageable safety profile, avoiding the severe toxicities that have limited the use of high-dose IL-2.
Syndax Expands Revuforj's Reach
Syndax Pharmaceuticals will have an oral presentation highlighting favorable outcomes for patients who received its newly approved menin inhibitor, Revuforj (revumenib), as a maintenance therapy after an allogeneic stem cell transplant. The data, from 21 patients with acute leukemia, addresses an area of high physician interest and could help expand the drug's use beyond its current indication for relapsed or refractory disease.
SKB BIO's Double Feature
SKB BIO will have a strong presence with two oral presentations for pivotal studies. The first features its TROP2-targeting antibody-drug conjugate (ADC), sac-TMT, a class of therapy that has seen intense interest and M&A activity. The second will highlight its next-generation selective RET inhibitor, A400/EP0031. Both are being studied in metastatic non-small cell lung cancer, signaling the potential for SKB BIO to emerge as a key player in the competitive lung cancer market.
This article is for informational purposes only and does not constitute investment advice.
